Latest News

March 2019: ERCS Conference

Epigem’s Marie Slodowska-Curie Research Fellow Niamh Kilcawley and Director Tim Ryan this month attended the European Red Cell Research Society (ERCS) meeting in Ascona, Switzerland. Niamh presented a poster and an oral presentation describing Epigem’s development of a novel microfluidic instrument (MeCheM) for the screening and diagnosis of red blood cell disorders such as rare anaemias.

January 2019: Epigem funded to fight antimicrobial resistance

Epigem is a partner in a new project to address the issue of antibiotic resistance. The project has been funded by Innovate UK as one of a number of ‘UK-China partnerships against antimicrobial resistance’. Epigem will be working with Glasgow and Oxford Universities in the UK, and a number of clinical partners in China, to develop a microfluidics-driven test that will incorporate advanced Raman spectroscopy to characterise antimicrobial resistance.

November 2018: Investors in People accreditation re-affirmed

Following a number of visits from the Investors in People team, and interviews with a selection of our staff, Epigem’s accreditation against the latest IIP standard has been confirmed

December 2017: Clinical trial launched

Epigem and CoMMiTMenT partner UZH launched the combined Memantine/MeChem trial in Afula Hospital, Israel. MeChem is the result of both partners’ collaborative work within the EU-funded CoMMiTMenT project. The diagnostic device could help identify which patients are most likely to benefit from the tested medicine and monitor the impact of different treatment doses on patients and prevention strategies. It could also have applications to other diseases, such as diabetes.

Anna Bogdanova from UZH and Tim Ryan of Epigem were present at the launch in Israel.

October 2017: Certification to ISO9001:2015 achieved

Epigem’s transition to the latest version of the ISO9001 Quality Standard has been completed, and following an audit by BSI this month our certification to ISO9001:2015 was confirmed.

May 2017: New Director of Operations appointed

Epigem today, Wednesday 3rd May announced the appointment of Marc Magnus as its Director of Operations. Marc’s main role is to support the company as it standardises and increases its manufacturing capability, giving its customers a complete service from concept, design, prototype to volume production.

Marc has twenty years’ experience in leading multi-functional teams across many manufacturing and operational disciplines, including chemical lines, printed circuit boards, mechanical CNC, electrical testing and final inspection techniques. This included a management board position for Snorkel, a leading global manufacturer of aerial work platforms.

Tim Ryan, managing director of Epigem, said: “Marc brings a wealth of experience and expertise in the operation of a modern manufacturing supply chain. I am looking forward to working with him closely in the coming months and years as we drive Epigem forward into its next phase of growth.”

Marc said: “I am extremely excited and proud to be joining Epigem at such a transitional phase and I am sure my operational experience will assist greatly in the company achieving its long-term goals.”

October 2016: US Patent on Composite Elelctrode granted

Epigem has been granted a patent by the US Patent and Trademark Office for its composite electrode.

The electrode has many innovative applications, including as a transparent conducting film. It can be designed to allow 95 per cent of light through, with a conductivity at least 10 times higher than that of indium tin oxide (ITO) coated film (for the same transparency). It improves conductivity owing to its innovative co-continuous layer of metal wires, too thin to see, which are perfectly embedded into a polymer insulator to nanometer precision.

The composite electrode has been validated in trials for the manufacture of solar panels, lighting, touchscreens and displays, as well as in healthcare, diagnostics and measurement where, for instance, a smooth surface is required to grow biological cells, such as nerve cells.

The composite electrode uses additive manufacturing with recognised associated environmental benefits. Unlike subtractive methods produced using copper foil laminates, which generate lots of waste by etching away what is not wanted, the metal in Epigem’s composite electrode is only deposited, where needed, in tiny channels in the embedding polymer, so there is no waste.

Owing to its versatility, Epigem’s composite electrode can be made into any pattern and its smooth planar surface means it is ideal for over-coating, whilst its mesh form provides strength and fault tolerance.

September 2016: Appointment of Marie Sklodowska-Curie Research Fellow Niamh Kilcawley

Miss Kilcawley, from Dublin, has been appointed as a Marie Skłodowska-Curie fellow in Epigem as part of the EU-funded RELEVANCE project. Niamh will be developing microfluidic devices for the diagnoses of rare anaemic conditions, such as Sickle Cell Anaemia and Thalassemia.

She will be collaborating with a team of 15 fellows across Europe at leading blood research centres, including clinicians and blood transfusion experts. Miss Kilcawley said: “Using microfluidic devices will allow us to use tiny volumes of blood and screen them in order to diagnose rare conditions.”

Miss Kilcawley’s interest in microfluidics began at Dublin City University, Ireland, where she said she found her feet as a researcher while studying to complete her undergraduate degree in Physics with Biomedical Sciences. She added: “It really opened my mind up to see what can be done with tiny amounts of fluid, particularly when it comes to medical diagnoses.